User login
Key abstracts on multiple sclerosis treatment from the 2023 European Committee for Treatment and Research in Multiple Sclerosis–Americas Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-ACTRIMS) meeting are reported by Dr Ellen Mowry of Johns Hopkins University.
Dr Mowry begins with a convenient alternative method of drug administration in patients with multiple sclerosis (MS). The phase 3 OCARINA II randomized trial showed promising results in safety and efficacy of subcutaneous ocrelizumab vs traditional longer intravenous infusion. Ocrelizumab is pending US Food and Drug Administration approval.
Next, Dr Mowry highlights two studies that examined known increased risks associated with anti-CD20 therapies. Dr Mowry discusses the importance of continued research into monitoring immunoglobin levels to determine dose escalation or extended interval dosing in patients with MS.
She then discusses the NEXT MS trial that looked at personalized dosing of natalizumab. The interim data indicate a dosing schedule that aims to maintain blood levels of the drug above a certain threshold appears as effective in controlling disease activity in relapsing-remitting MS (RRMS) as the approved 4-week dosing schedule.
Finally, Dr Mowry discusses a phase 2 randomized trial of the gold nanoparticle CNM-Au8, which has been used to treat other autoimmune diseases, to determine its potential benefits in RRMS.
--
Ellen Mowry, MD, MCR, Professor of Neurology & Epidemiology, Johns Hopkins University, Baltimore, Maryland
Ellen Mowry, MD, MCR, has disclosed the following relevant financial relationships:
Serve(d) as a consultant for: BeCareLink, LLC
Received research grant from: Biogen; Genentech
Received royalties from: UpToDate
Key abstracts on multiple sclerosis treatment from the 2023 European Committee for Treatment and Research in Multiple Sclerosis–Americas Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-ACTRIMS) meeting are reported by Dr Ellen Mowry of Johns Hopkins University.
Dr Mowry begins with a convenient alternative method of drug administration in patients with multiple sclerosis (MS). The phase 3 OCARINA II randomized trial showed promising results in safety and efficacy of subcutaneous ocrelizumab vs traditional longer intravenous infusion. Ocrelizumab is pending US Food and Drug Administration approval.
Next, Dr Mowry highlights two studies that examined known increased risks associated with anti-CD20 therapies. Dr Mowry discusses the importance of continued research into monitoring immunoglobin levels to determine dose escalation or extended interval dosing in patients with MS.
She then discusses the NEXT MS trial that looked at personalized dosing of natalizumab. The interim data indicate a dosing schedule that aims to maintain blood levels of the drug above a certain threshold appears as effective in controlling disease activity in relapsing-remitting MS (RRMS) as the approved 4-week dosing schedule.
Finally, Dr Mowry discusses a phase 2 randomized trial of the gold nanoparticle CNM-Au8, which has been used to treat other autoimmune diseases, to determine its potential benefits in RRMS.
--
Ellen Mowry, MD, MCR, Professor of Neurology & Epidemiology, Johns Hopkins University, Baltimore, Maryland
Ellen Mowry, MD, MCR, has disclosed the following relevant financial relationships:
Serve(d) as a consultant for: BeCareLink, LLC
Received research grant from: Biogen; Genentech
Received royalties from: UpToDate
Key abstracts on multiple sclerosis treatment from the 2023 European Committee for Treatment and Research in Multiple Sclerosis–Americas Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-ACTRIMS) meeting are reported by Dr Ellen Mowry of Johns Hopkins University.
Dr Mowry begins with a convenient alternative method of drug administration in patients with multiple sclerosis (MS). The phase 3 OCARINA II randomized trial showed promising results in safety and efficacy of subcutaneous ocrelizumab vs traditional longer intravenous infusion. Ocrelizumab is pending US Food and Drug Administration approval.
Next, Dr Mowry highlights two studies that examined known increased risks associated with anti-CD20 therapies. Dr Mowry discusses the importance of continued research into monitoring immunoglobin levels to determine dose escalation or extended interval dosing in patients with MS.
She then discusses the NEXT MS trial that looked at personalized dosing of natalizumab. The interim data indicate a dosing schedule that aims to maintain blood levels of the drug above a certain threshold appears as effective in controlling disease activity in relapsing-remitting MS (RRMS) as the approved 4-week dosing schedule.
Finally, Dr Mowry discusses a phase 2 randomized trial of the gold nanoparticle CNM-Au8, which has been used to treat other autoimmune diseases, to determine its potential benefits in RRMS.
--
Ellen Mowry, MD, MCR, Professor of Neurology & Epidemiology, Johns Hopkins University, Baltimore, Maryland
Ellen Mowry, MD, MCR, has disclosed the following relevant financial relationships:
Serve(d) as a consultant for: BeCareLink, LLC
Received research grant from: Biogen; Genentech
Received royalties from: UpToDate
